Third-line therapy for metastatic colorectal cancer M. G. GundgaardJ. B. SoerensenE. Ehrnrooth Review 05 September 2007 Pages: 1 - 13
Modification of multidrug resistance of tumor cells by ionizing radiation Yuri N. KorystovVera V. ShaposhnikovaLudmila N. Kublik Original Article 14 March 2007 Pages: 15 - 21
The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers Rob J. JonesTamsin BoyceJohn Robertson Original Article 20 March 2007 Pages: 23 - 32
Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy Li ZhangYang ZhangZhong-Zhen Guan Original Article 20 March 2007 Pages: 33 - 38
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin Alfred F. FurthSumithra J. MandrekarJoel M. Reid Original Article 20 March 2007 Pages: 39 - 45
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas Jeeyun LeeTae-You Kimon behalf of the Korean Cancer Study Group Original Article 16 March 2007 Pages: 47 - 52
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer Yoshihiro WadaKen KikuchiShoichi Ueda Original Article 21 March 2007 Pages: 53 - 61
Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate Lee JiaLori C. CowardJohn C. Reed Original Article 14 March 2007 Pages: 63 - 73
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer Sang Joon ShinJoong Bae AhnJae Kyung Roh Original Article 21 March 2007 Pages: 75 - 81
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus Dae Ho LeeHeung Tae KimJin Soo Lee Original Article 28 April 2007 Pages: 83 - 88
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice Roni HaklaiGalit Elad-SfadiaYoel Kloog Original Article 20 March 2007 Pages: 89 - 96
Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction Martina BaurAnne DrescherUlrich Jaehde Original Article 30 March 2007 Pages: 97 - 104
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin Roberto PetrioliAlessandra PascucciGuido Francini Original Article 12 April 2007 Pages: 105 - 111
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring G. VassalG. MichelC. Puozzo Original Article 29 March 2007 Pages: 113 - 123
A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer T. O’ConnorY. RustumP. Creaven Original Article 11 April 2007 Pages: 125 - 131
Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(ε-caprolactone) micelles of rapamycin Jaime A. YáñezM. Laird ForrestNeal M. Davies Original Article 29 March 2007 Pages: 133 - 144
Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria N. A. G. SantosC. S. Catão BezerraA. C. Santos Original Article 30 March 2007 Pages: 145 - 155
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer Sang Joon ShinHei-Cheul JeungHyun Cheol Chung Original Article 11 April 2007 Pages: 157 - 165
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis Robert L. FineDavid R. FogelmanJohn Chabot Clinical Trial Report 18 April 2007 Pages: 167 - 175
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis Robert L. FineDavid R. FogelmanJohn Chabot Erratum 09 September 2007 Pages: 177 - 177
